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Summary
Introduction Treatment for erythema nodosum leprosum (ENL), an immunological
complication of leprosy, is diverse. We undertook a systematic review as it was not
clear which treatments were most beneficial.
Methods We did a systematic search to identify randomised controlled trials
(RCTs) comparing treatment with placebo, no treatment or another therapy. Two
authors assessed quality and checked data.
Results We included 13 studies involving 445 participants. These trials assessed:
betamethasone, thalidomide, pentoxifylline, clofazimine, indomethacin and
levamisole. The quality of the trials was generally poor and no results could be
pooled due to the treatments being so heterogeneous. Treatment with thalidomide
showed a significant benefit compared to aspirin (RR 2·43; 95% CI 1·28 to 4·59).
Clofazimine treatment was superior to prednisolone (more treatment successes;
RR 3·67; 95% CI 1·36 to 9·91) and thalidomide (fewer recurrences; RR 0·08; 95%
CI 0·01, 0·56). Minor adverse events were significantly lower in participants on a
low dose thalidomide regimen compared to a high dose thalidomide regimen
(RR 0·46; 95% CI 0·23 to 0·93). Significantly more minor adverse events
were reported in participants taking clofazimine compared with prednisolone (RR
1·92; 95% CI 1·10 to 3·35). None of the studies assessed quality of life or
economic outcomes.
Conclusion There is some evidence of benefit for thalidomide and clofazimine, but
generally we did not find clear benefits for interventions in the management of ENL.
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This does not mean they do not work because the studies were small and poorly
reported. Larger studies using clear definitions and internationally recognised scales
are urgently required.
Introduction
This paper is based on a Cochrane review first published in The Cochrane Library 2009,
Issue 3 (see http://www.thecochranelibrary.com/ for information). Cochrane reviews are
regularly updated as new evidence emerges and in response to feedback, and The Cochrane
Library should be consulted for the most recent version of the review.
Erythema nodosum leprosum (ENL) or Type 2 leprosy reaction is an immune-mediated
complication of leprosy, causing inflammation of skin, nerves and other organs, and general
malaise.1 – 3 ENL only occurs in people with borderline lepromatous (BL) and lepromatous
(LL) leprosy. These people have high bacterial loads which increase the risk of ENL. The
reported prevalence of ENL among these people is highly variable with high rates (up to
50%) in Asia4 and lower rates (up to 12%) in Africa.5 Most people with ENL have multiple
acute episodes of ENL or chronic ENL over several years. Few people experience a single
acute episode of ENL.4
Therapies for ENL aim to control the acute inflammation, relieving the pain and preventing
further nerve damage or new episodes. The conventional treatment for mild ENL is rest and
anti-inflammatory medication. Aspirin is the most commonly used anti-inflammatory drug, but
indomethacin, chloroquine and colchicine have been tested as well.2,6 For severe ENL,
prednisolone and clofazimine are most commonly used. Prednisolone usually acts rapidly by
controlling the acute inflammation and relieving the pain. The starting dose should be the
lowest possible to control ENL and be gradually reduced. The schedule for reducing
prednisolone depends on the course of the disease. ENL is often recurrent or chronic and
requires high-dose and prolonged courses of prednisolone for the disease to be controlled. This
increases the risk of adverse events, such as hypertension or diabetes, and steroid dependency.2,
6 Clofazimine is considered a useful anti-inflammatory drug when corticosteroids are
contraindicated or need to be reduced. However, treatment with clofazimine usually takes 4 to
6 weeks to become active and the dose of clofazimine needed to control ENL is higher than the
dose used in multi drug therapy (MDT). Disadvantages of continuous high doses of
clofazimine are gastrointestinal symptoms (e.g. diarrhoea) and dark discoloration of the skin.2,
6,7 Another drug used to treat ENL is thalidomide. The effectiveness of thalidomide in ENL is
primarily due to its action on the proflammatory cytokine TNF but other mechanisms may
contribute to its anti-inflammatory effect.8 The seventh WHO Expert Committee on Leprosy
considered thalidomide as an effective treatment of severe ENL, and recommended to restrict
thalidomide treatment to male or post-menopausal female patients only. Thalidomide should
only be given to women of childbearing age when comprehensive contraceptive precautions
can be taken, because its use may cause serious birth defects when taken in early pregnancy.9
ENL is a serious immunological complication of leprosy. The complex mechanisms
underlying ENL are not fully understood yet, which makes treatment difficult.
Corticosteroids, clofazimine and thalidomide are the drugs of choice for ENL, but all have
drawbacks and the optimal regimen has not been established. Alternative therapies (e.g.
ciclosporin, oral zinc) have been tested, but it is unclear if they are beneficial, or which one is
preferable. The role of newer treatments, such as TNF-a antibody treatment, intravenous
immunoglobulin, and tenidap, is not known.
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Methods
SEARCH STRATEGY
We searched the Cochrane Skin Group Specialised Register using the following search terms:
(leprosy and Type and 2) or lepromatous or lepra* or (erythema and nodosum) or ‘ENL’ or
(leprosy and borderline) or leprosum. This search strategy, combined with a search strategy for
identifying randomised trials, was adapted to include additional search terms where necessary
and was modified to search the Cochrane Central Register of Controlled Trials (Cochrane
Library, Issue 1, 2009), MEDLINE (from 2003), EMBASE (from 2005), LILACS and AMED
(from inception), CINAHL (from 1981) and databases of ongoing trials. All searches were
done in March 2009. We checked reference lists of articles. We contacted a person to locate
studies from Brazil. There were no language restrictions. Two authors checked the titles and
abstracts of all the publications identified to examine which studies were eligible.
STUDY SELECTION
Studies were eligible if they were randomised controlled trials (RCTs) assessing any therapy
for ENL, including systemic corticosteroids, systemic non-steroidal immunomodulatory
therapies and diverse therapies. We used the following definition of ENL: ‘an inflammatory
condition, in which people develop crops of tender erythematous subcutaneous skin lesions’.
There may be accompanying neuritis, iritis (inflammation of the iris), arthritis, orchitis
(inflammation of the testis), dactylitis (inflammation of the fingers and toes), lymphadeno-
pathy, oedema and fever. The skin signs are obligatory; the nerve and general signs
optional.10,11 The primary outcome measure of interest was the proportion of participants
achieving remission of skin lesions. Remission was defined as the absence of new tender
erythematous subcutaneous skin lesions at completion of the ENL therapy, as assessed by a
clinician. Secondary outcome measures were: the proportion of participants achieving
remission of inflammations at other sites, investigator-assessed change in ENL severity, time
to next clinical episode of ENL and changes in quality of life. We considered data that had
been recorded for 4 weeks or less from the start of treatment to reflect short-term benefit and
these were analysed separately from data that were recorded for more than 4 weeks from the
start of treatment, which we considered to reflect the minimum time period to capture any
longer-term benefit. The short-term assessment (1 to 4 weeks) was considered the primary
endpoint, because the definite treatment effects should be visible within the first few weeks.
The medium-term assessment (between 4 weeks and 6 months) was used as a secondary
endpoint. Assessments of more than 6 months after the start of treatment were considered
long-term outcomes.
METHODOLOGICAL QUALITY
The methodological quality of the included studies was based on the following criteria: the
method of generation of the randomisation sequence; the method of allocation concealment;
who was blinded/not blinded (participants, clinicians, outcome assessors); how many
participants were lost to follow-up in each arm and whether participants were analysed in the
groups to which they were originally randomised (intention to treat principle); degree of
certainty that participants had ENL; baseline comparison for age, sex, duration and severity
of ENL; whether outcome measures were clearly described.
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Each criterion was assessed as A: adequate, B: unclear or C: inadequate. If one of the
criteria was not described in the study, it was labelled ‘inadequate’. Two authors
independently assessed the included studies for methodological quality.
DATA EXTRACTION AND ANALYSIS
One author extracted data regarding methodology and outcome measures from the included
studies onto a data extraction form, and a second author checked the data. If there were
missing data, the trial authors were contacted. Authors were not blinded to trial author,
journal or institution. We used the Cochrane statistical package, Review Manager, for
statistical data analysis. Results were expressed as mean differences with 95% confidence
intervals (CI) for continuous outcome measures and relative risks (RR) with 95% CI for
dichotomous outcomes. We were not able to pool results from studies due to treatments and
outcomes being so heterogeneous, and did not perform sensitivity analysis. We did not
perform further subgroup analysis due to lack of data on different subgroups (mild versus
severe ENL; single acute versus multiple acute versus chronic ENL). Adverse effects that
were reported in the included studies were described.
Results
STUDY SELECTION
We found 269 citations to potentially relevant trials from the electronic searches. Eight
potentially eligible studies were found from references of included trials and reviews.
Correspondence with authors and other people, and searching of grey literature revealed
one potentially relevant trial. We identified 48 possible studies, of which 13 were RCTs.
The search of the ongoing trial registers revealed one ongoing trial. We excluded 35 studies
of which 21 were not RCTs, two were excluded as they did randomisation by alternation,
10 did not have ENL as inclusion criterion, but included participants with lepromatous
leprosy in general, one was a duplicate study and one was excluded because it described only
intake results and was not completed.
CHARACTERISTICS OF INCLUDED STUDIES
We included 13 trials with 445 participants in this review and characteristics of these studies
are shown in Table 1.
Ten studies were published between 1969 and 1985 and three studies between 2002 and
2007. Three trials had a cross-over design and 10 trials had a parallel group design, of which
one trial had four parallel groups. The studies involved sample sizes between nine and
92 participants. Two studies randomised and evaluated ENL reactions of participants. The age
range of participants in eight studies was 14 to 69 years, five studies did not report
information on the age of the participants. Five studies included both males and females,
four studies included only males, and four studies did not report this information. The
duration of ENL reactions varied from 0–12·5 years in eight trials, and five trials did not
report this information. The severity of reactions ranged from mild to severe and was reported
in eight trials.
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Table 1. Characteristics of included studies
Study Method Participants Interventions Outcomes
Girdhar 2002 Parallel
group design
Setting: single centre, leprosy
centre, India
Incl: lepromatous leprosy wit recurrent
ENL and on steroids for . 6 months,
excl: not stated
M/F: not stated, age: not stated, duration:
not stated, severity: not stated
Randomised: 10 participants
Evaluable: 9 participants
(1 lost to follow-up)
Experimental group (n ¼ 4): infusion
of betamethasone in 5% dextrose daily
for 3 days every 4 weeks for 6 months
Control group (n ¼ 5): infusion of 5% dextrose
daily for 3 days every 4 weeks for 6 months
Other therapy: MDT with 100 mg clofazimine
daily for all participants; oral steroids as
per need to control ENL for participants
in control group
1) Change in severity and frequency
of ENL 6 months after end
of treatment
2) Steroid requirement
3) Side effects
Pearson 1969 Cross over
design
Setting: single centre, leprosy
centre, Malaysia
Incl: moderately severe ENL,
Excl: not stated
M/F: 11/1, age: not stated, duration:
10 months to 3·5 years, severity: unclear,
though title states was moderately severe
ENL
Randomised: 12 participants
Evaluable: 12 participants (1 from group
B withdrawn from study
after 9 weeks)
Group A (n ¼ not stated): thalidomide tablets
(100 mg 3 times daily) for 6 weeks, followed by
placebo (dose and frequency unknown)
for 6 weeks
Group B (n ¼ not stated): placebo tablets (dose
and frequency not stated) for 6 weeks, followed
by thalidomide tablets (100 mg 3 times daily) for
6 weeks
Other therapy: prednisolone, stibophen and
paracetamol in addition to placebo
1) Change in ENL score
2) Steroid requirement
3) Side effects
Waters 1971 Cross over
design
Setting: single centre, leprosy centre,
Malaysia
16-week trial (n ¼ 9) and 24-week
trial (n ¼ 8):
1) Steroid requirement during
trial period
Incl: not stated, but included were
participants with lepromatous leprosy
and histologically confirmed moderately
severe or severe chronic ENL, excl: not
stated
M/F: 10 M, age: 19–56, duration:
9 months to 3·5 years, severity:
moderately severe or severe chronic ENL
Randomised and evaluable: 9
participants (16-week trial), 8
participants (24-week trial)
Group A (n ¼ 5 or n ¼ 3): thalidomide tablets
(100 mg 3 times daily) for 4 or 6 weeks, followed
by placebo tablets (dose unknown, 3 times daily)
for 4 or 6 weeks
Group B (n ¼ 4 or n ¼ 5): placebo tablets (dose
unknown, 3 times daily) for 4 or 6 weeks,
followed by thalidomide tablets (100 mg 3 times
daily) for 4 or 6 weeks
Other therapy: 100 mg DDS twice weekly,
prednisolone or corticotrophin daily, mild
analgesics if needed
2) ENL score (temperature, severity)
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Table 1. continued
Study Method Participants Interventions Outcomes
Sheskin 1969 Parallel
group design
Setting: single centre,
hospital/ambulatory, Venezuela
Incl: lepromatous leprosy with clearly
demonstrable dermatologic, neurologic
or other manifestations
of ENL reaction, excl: not stated
M/F: 37/15, age: 17–58, duration: 3
months to 9 years, severity: not stated
Randomised and evaluable: 173 ENL
reactions (of 52 participants)
Experimental group (n ¼ 85): thalidomide
tablets (100 mg 4 times daily if . 50 kg, or
6 mg/kg/day if # 50 kg) for 7 days
Control group (n ¼ 88): placebo tablets (100 mg
4 times daily if . 50 kg, or 6 mg/kg/day
if # 50 kg) for 7 days
Other therapy: if on sulfone therapy at
admission, sulfone therapy was continued; if
receiving steroids or ACTH for prolonged
periods at admission, same dosage was continued
1) Total improvement, defined
as all dermatologic manifestations
in advanced
state of remission, no new elements,
disappearance of characteristic lepra
reaction symptoms after 7 days
2) Side effects
Iyer 1971 Parallel
group design
Setting: multicentre, 4 centres, India,
Mali, Somalia, Spain
Incl: clearly demonstrable
dermatological signs of acute lepra
reactions, excl: severe or life-threatening
lepra reactions
M/F: 92 M, age: 15–55 þ , duration:
not stated, severity: not stated
Randomised and evaluable: 214 ENL
reactions (of 92 participants)
Experimental group (n ¼ 116): thalidomide
tablets (100 mg 4 times daily if $ 50 kg, or
100 mg 1–3 times daily if , 50 kg) for 7 days
Control group (n ¼ 98): acetylsalicyclic acid
tablets (400 mg 4 times daily if $ 50 kg, or
400 mg 1–3 times daily if , 50 kg) for 7 days
Other therapy: upon admission all
drug therapy had to be ceased
1) No further reactions
2) Changes in temperature, skin
lesions, blood pressure, pulse rate
and blood cell count after 7 days
3) Side effects
Villahermosa
2005
Parallel
group design
Setting: single centre, leprosy
centre, Philippines
Incl: lepromatous leprosy, $18 years,
acute histologically confirmed episode of
ENL consisting of $ 10 skin nodules,
with or without systemic symptoms;
women only included if evidence of
non–childbearing potential, excl:
incapacitating ENL (bed ridden), severe
neuritis, thalidomide ingestion within
30 days or corticosteroid ingestion
within 2 weeks of enrolment
M/F: 22 M, age: 18–46, duration:
0–3 years, severity: not stated
Randomised: 22 participants
Evaluable: 19 (3 lost to follow-up)
Group A (n ¼ 12): thalidomide capsules, 100 mg
daily (2 £ 50 mg, 4 £ dummy capsules) in
week 1, 50 mg daily (1 £ 50 mg, 3 £ dummy
capsules) in week 2–3, 4 £ dummy capsules
daily in week 4–7
Group B (n ¼ 10): thalidomide capsules, 300 mg
daily (6 £ 50 mg, 0 £ dummy capsules) in
week 1, 200 mg daily (4 £ 50 mg, 0 £ dummy
capsules) in week 2–3, 100 mg daily
(2 £ 50 mg, 2 £ dummy capsules) in week
4–5, 50 mg daily (1 £ 50 mg, 3 £ dummy
capsules) in week 6–7
Other therapy: acetaminophen for participants
with fever during first 72 h of study
1) Resolution of inflamed ENL
nodules during initial
7-day treatment
2) Global assessment
3) Re-emergence of skin lesions
during taper
4) Week 7 lesion counts
5) Recurrence of lesions after taper
6) Safety and adverse events
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Table 1. continued
Study Method Participants Interventions Outcomes
Sales 2007 Parallel
group design
Setting: single centre, leprosy
centre, Brasil
Incl: MB leposy, males between
18–60 y, females over 49
(postmenopausal), clincal and
histopathological ENL, excl: acute
neuritis requiring CS, hepatic, renal,
mental diseases, diabetes and/or
immune-deficiencies related to HIV
M/F: 38/6, age: 18–69, duration:
not stated, severity: not stated
Randomised: 44 participants
Evaluable: 44 participants
(8 lost to follow-up)
Group A (n ¼ 24): pentoxifylline
(1·2 g daily) for 30 days
Group B (n ¼ 20): thalidomide
(300 mg daily) for 30 days
Other therapy: participants with no
improvement after 15 days treatment
or with severe adverse effects were
removed from study and put on
recommended regimen of thalidomide
or corticosteroids
1) Improvement at end of 30 days
treatment, defined as complete
elimination of type 2 reactional skin
lesion inflammation, normal body
temperature and/or regression of
systemic symptoms
2) Side effects
Helmy 1971 Cross over
design
Setting: single centre, leprosy centre,
Malaysia
Incl: not stated, though included were
lepromatous or indefinite leprosy with
moderately severe ENL, excl: not stated
M/F: 10/5, age: 17–67, duration: 6
months to 2 years, severity: moderately
severe ENL
Randomised: 15 participants
Evaluable: 10 participants
(5 lost to follow-up)
Group A (n ¼ 3): clofazimine capsules
(100 mg 3 times daily) in week 1–4,
followed by placebo capsules
(dose unknown, 3 times daily) in week 5–8
Group B (n ¼ 7): placebo capsules (100 mg
3 times daily) in week 1–4, followed by
clofazimine capsules (dose unknown, 3 times
daily) in week 5–8
Other therapy: dapsone (100 mg 2 times daily);
stibophen if needed; paracetamol issued twice
weekly to be taken freely
1) Severity score of ENL
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Table 1. continued
Study Method Participants Interventions Outcomes
Iyer 1976 Parallel
group design
Setting: single centre, India
Incl: male, lepromatous leprosy and
prone to recurrent reactive episodes,
excl: not stated
M/F: 72 M, age: 15–54, duration:
,6 months to . 4 years, severity:
moderate, severe
Randomised: unclear, states ‘72
participants available for analysis’
Evaluable: 72 participants
Experimental group (n ¼ 36): clofazimine
(100 mg 3 times daily)
for 8 weeks, clofazimine (100 mg
once a day) þ dapsone (10 mg/kg/week)
for 52 weeks
Control group (n ¼ 36): thalidomide
(100 mg 3 times daily) for 8 weeks,
thalidomide (25–50 mg once a day)
þ dapsone (10 mg/kg/week) for 52 weeks
Other therapy: dapsone (10 mg/kg/week)
for 52 weeks
1) Time to control reaction
2) Maintenance of anti-reaction
effect after therapy
Karat 1970 Parallel
group design
Setting: single centre, leprosy
centre, India
Incl: history of $ 3 severe reactions and
with severe current reaction which could
not be controlled by antimony, aspirin or
chloroquine, excl: peptic ulcer,
intercurrent acute infections, TB or
malignant lesions
M/F: not stated, age: not stated, duration:
4–150 months, severity: severe
Randomised and evaluable: 24
participants
Experimental group (n ¼ 12): clofazimine
(100 mg 3 times daily) for 12 weeks
Control group (n ¼ 12): prednisolone (10 mg 3
times daily) week 1, (10 mg 2 times daily) week
2, (5 mg 3 times daily) week 3, (10 mg 2 times
daily) week 4, (5 mg once daily) week 5–12
Other therapy: none
1) Treatment success at end of
12 weeks, defined as body
temp , 37·2 8C, no new
ENL lesions, no pain in peripheral
nerve, no progression of neurological
deficit, and iritis quiescent in
2 weeks from starting treatment
2) Recurrence of reaction during trial
3) Side effects
Ing 1969 Parallel
group design
Setting: single centre, Singapore
Incl: Lepromatous leprosy and ENL
(mild, moderate or severe), excl:
not stated
M/F: not stated, age: not stated, duration:
not stated, severity: 15 mild, 9 moderate,
6 severe
Randomised: 30 participants
Evaluable: 30 participants, though one
participants did not complete
4-week treatment
Experimental group (n ¼ 16): indomethacin
(25 mg 3 times daily)
for 1 month
Control group (n ¼ 14): prednisolone (5 mg
3 times daily) for 1 month
Other therapy: anti-leprosy drugs were given
during 4-week trial period, but
no additional analgesics
1) Improvement after 4 weeks
(e.g. mean change in pain relief,
subsidence of lesions)
2) Side effects
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Table 1. continued
Study Method Participants Interventions Outcomes
Karat 1969 Parallel
group design
Setting: single centre, leprosy centre,
India
Incl: lepromatous leprosy with ENL,
.12 years, excl: history or radiological
evidence of peptic ulcer, diabetes, TB,
hypertension, severe intercurrent
infection, acute peripheral nerve
paralysis, medical conditions requiring
use of other anti-leprosy drugs
M/F: not stated, age: not stated, duration:
not stated, severity: 28 mild, 22 severe
Randomised and evaluable: 50
participants
Group 1 (n ¼ 11): indomethacin orally
(50 mg 3 times daily) in wk 1–2, (25 mg
3 times daily) in week 3, (25 mg once a
day) maintenance
Group 2 (n ¼ 12): chloroquine orally
(250 mg 3 times daily) in wk 1–2,
(250 mg 2 times daily) in week 3,
(250 mg once a day) maintenance
Group 3 (n ¼ 13): prednisolone orally
(5 mg 3 times daily) in wk 1–2,
(5 mg 2 times daily) in week 3,
(5 mg once a day) maintenance
Group 4 (n ¼ 14): aspirin orally (1 g
3 times daily) in wk 1–2, (1 g 2 times daily)
in week 3, (500 mg 2 times daily) maintenance
Other therapy: anti-leprosy drugs were
stopped on admission; sedation with
phenobarbitone or chlorpromazine if
needed; diuretics only when oedema
was progressive and uncontrolled
by one of the given drugs
1) Control of reaction
2) Recurrence of reaction
3) Side effects
Arora 1985 Parallel
group design
Setting: single centre, hospital, India
Incl: 12 participants with ENL,
excl: not stated
M/F: 11/1, age: 14–55, duration: 0–7
years, severity: severe
Persons analysed: 269 (a: 88, b: 91, c: 90)
Randomised and evaluable: 12
participants
Experimental group (n ¼ 5): levamisole
capsules (150 mg daily) on 3 consecutive
days repeating every fortnight for 3 months
Control group (n ¼ 7): placebo
capsules (dose unknown, daily) on
3 consecutive days repeating every
fortnight for 3 months
Other therapy: iron for anaemic participants
1) Improvement, defined as
complete recovery from reaction,
after 3 months
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INTERVENTIONS
The included studies examined the following interventions.
Systemic corticosteroids:
. infusion of betamethasone in 5% dextrose versus infusion of 5% dextrose12
Systemic non-steroidal immunomodulatory therapies:
. thalidomide versus placebo13 – 15
. thalidomide versus acetylsalicylic acid16
. 100 mg thalidomide regimen versus 300 mg thalidomide regimen17
. pentoxifylline versus thalidomide18
. clofazimine versus placebo19
. clofazimine versus thalidomide20
. clofazimine versus prednisolone21
. indomethacin versus prednisolone22
. indomethacin versus chloroquine versus prednisolone versus aspirin23
. levamisole versus placebo24
Diverse therapies:
. none
OUTCOME MEASURES
The outcomes remission of skin lesions and remission of inflammation at other sites were not
explicitly reported in any of the trials. Seven trials used different grading scales or scores to
assess ENL severity. The secondary outcome of time to next clinical episode was not reported
in any of the trials. None of the studies measured changes in quality of life or economic
outcomes. Adverse effects were not reported in three trials.
Six trials recorded data only for 4 weeks or less from the start of treatment, reflecting short-
term benefit. Three trials had the outcome assessment at medium term, ranging from 4 weeks to
6 months from the start of treatment. One trial assessed long-term benefit, more than six months
after treatment. One trial assessed both on short-term and medium-term, and one trial both on
medium-term and long-term. The timing of outcome assessment was unclear in one trial.
METHODOLOGICAL QUALITY
The methodological quality of the trials was generally poor. The results of the assessment of
methodological quality are shown in Table 2.
None of the trials was clear as to how randomisation lists were generated. Concealment of
allocation was considered adequate in two trials which had the medication pre-prepared by a
drug company.16,17
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Table 2. Assessment of methodological quality
Study
Adequate sequence
generation
Allocation
concealment Blinding
Incomplete outcome
data addressed
Free of selective
reporting
Free of other
bias*
Girdhar 2002 Unclear Unclear Unclear Unclear Yes Unclear
Pearson 1969 Unclear Unclear Unclear Yes No Unclear
Waters 1971 Unclear Unclear Unclear Unclear No Unclear
Sheskin 1969 Unclear Unclear Unclear Unclear Yes Unclear
Iyer 1971 Unclear Yes Unclear Unclear Unclear Unclear
Villahermosa 2005 Unclear Yes Unclear No Yes Unclear
Sales 2007 Unclear Unclear Unclear Yes Yes Unclear
Helmy 1971 Unclear Unclear Unclear No Unclear Unclear
Iyer 1976 Unclear Unclear No Unclear Unclear Unclear
Karat 1970 Unclear Unclear Unclear Unclear Yes Yes
Ing 1969 Unclear Unclear Unclear Unclear No Unclear
Karat 1969 Unclear Unclear Unclear Unclear Yes Unclear
Arora 1985 Unclear Unclear Unclear Unclear Yes Unclear
* Certainty of diagnosis, baseline comparison, explicit outcomes.
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Blinding of outcome assessment was attempted for most of the trials, but none of the studies
clearly described who (the participants, clinicians and outcome assessors) was blinded.
Information about incomplete outcome data was generally not reported and participant
losses ranged between 0 and 33%. Seven trials did not report information on incomplete
outcome data, but if accepting no mention in the text and no signs of attrition in tables, as a
100% follow-up, all of these trials had a follow-up rate of 100%. Six trials reported missing
data and two performed intention to treat analysis.
Six trials did not perform a statistical analysis, but only described the results. One study22
reported in the summary that ‘indomethacin is effective in treating only mild and moderate
cases of ENL’. The summary of one study14 concluded that ‘nine of the 10 participants
showed a very significant improvement’. Another study13 summarised that ‘thalidomide was
superior to a placebo’. None of these studies provided sufficient evidence (e.g. significant test
values) to support these claims.
Five studies specified erythema nodosum leprosum (ENL) in their inclusion criteria. Most
other studies did not define ENL, but did mention it under the inclusion criteria. Five studies
did not provide data for baseline comparison and seven studies were not clear as to whether
groups were similar at baseline. Six studies did not clearly describe outcome measures.
EFFECTS OF INTERVENTIONS
Subgroup analysis was not performed as there were no appropriate studies to pool. Of the
13 studies included, none compared the same interventions or had comparable outcomes.
We did not find any trials assessing diverse therapies for ENL. Quality of life and economic
outcomes were not included in any of the trials.
Primary Outcome Measure
(A ) THE PROPORTION OF PARTICIPANTS ACHIEVING REMISSION OF SKIN
LESIONS
None of the studies reported the absence of new skin lesions at the end of therapy. Two
studies had outcome measures that were considered to reflect our primary outcome measure,
Karat et al.21 reported treatment success, including absence of new ENL lesions and Sheskin
et al.15 reported improvement, including absence of new ENL lesions, but did not provide
separate data of the first randomised treatment regimen for comparison. Five studies reporting
differing definitions of remission of skin lesions. One study reported the number of
participants with no further reaction after the first treatment regimen, implying absence of
new ENL skin lesions.16 Three studies reported the resolution of existing skin lesions.17,18,22
Systemic corticosteroids
Remission of skin lesions was not reported for any systemic corticosteroid interventions.
Systemic non-steroidal immunomodulatory therapies
Short-term: Significantly more participants who received thalidomide treatment had no
further reaction after 7 days, requiring a second treatment regimen, compared to those
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receiving acetylsalicylic acid (aspirin) treatment (RR 2·43; 95% CI 1·28 to 4·59; n ¼ 92).16
No significant difference in resolution of existing inflamed ENL nodules was found between
the 100 mg thalidomide regimen and the 300 mg thalidomide regimen after 7 days (RR 1·33;
95% CI 0·64 to 2·79; n ¼ 22).17 No significant difference in the resolution of existing
inflamed ENL skin nodules was observed between pentoxifylline and thalidomide after 30
days of treatment (RR 1·05; 95% CI 0·74 to 1·49; n ¼ 25).18 No significant difference in
complete subsidence of existing ENL lesions was found between indomethacin and
prednisolone after 4 weeks (RR 2·33; 95% CI 0·76 to 7·13; n ¼ 30).22
Medium-term: One participant, who had received the 300 mg thalidomide regimen, had a
successful taper, defined as a complete response after 7 days and lack of new acutely inflamed
lesions during the 6 week taper and for at least 2 months after stopping thalidomide.17
Significant more treatment successes were observed in the clofazimine group compared to the
prednisolone group at the end of 12 weeks of treatment (RR 3·67; 95% CI 1·36 to 9·91;
n ¼ 24).21
Secondary Outcome Measures
(A) THE PROPORTION OF PARTICIPANTS ACHIEVING REMISSION OF
INFLAMMATIONS AT OTHER SITES
Remission of inflammations at other sites was not reported in any of the studies, or
inadequately16 (no separate data of the first randomised treatment regimen).
(B ) INVESTIGATOR-ASSESSED CHANGE IN ENL SEVERITY
One study used a global assessment score to assess for changes in ENL symptoms
(anorexia, arthralgias, chills, malaise, neuritis, orchitis and fever).17 One study used a grading
scale (0–3) to assess changes in ENL severity, with higher grades indicating more severe
ENL.24 One study13 used an ENL severity score, but did not provide individual participant
data or means and standard deviations for comparison. Two studies assessed change in ENL
severity using different scoring methods, but provided only sum scores of the weekly scores
over the 4 weeks trial period.14,19 One study assessed the frequency and severity of ENL, but
did not provide data or significant test values for comparison.12 One study reported control of
reaction, but it was unclear how control was defined.23 It was unclear whether any of the
scales used had been formally validated.
Systemic corticosteroids
Change in ENL severity was not reported for any systemic corticosteroid interventions.
Systemic non-steroidal immunomodulatory therapies
Short-term: No significant difference in improvement (becoming asymptomatic) was found
between the 100 thalidomide regimen and the 300 mg thalidomide regimen after 7 days of
treatment (RR 1·67; 95% CI 0·85 to 3·26; n ¼ 22).17
Medium-term: No significant difference in improvement (change from grade 3 to grade 1
or 0) was observed between levamisole and placebo after 3 months (RR 0·95; 95% CI 0·36 to
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2·49; n ¼ 12).24 No significant difference in control of reaction was found between
indomethacin and chloroquine (RR 0·95; 95% CI 0·52 to 1·74; n ¼ 23), prednisolone (RR
0·65; 95% CI 0·41 to 1·02; n ¼ 24) and aspirin (RR 0·89; 95% CI 0·51 to 1·55; n ¼ 25)
respectively. The duration of the trial and timing of outcome assessment was unclear; the
paper stated both a trial period of 90 days and of 12 months.23
(C ) TIME TO NEXT CLINICAL EPISODE OF ENL
Time to next clinical episode of ENL was not reported in any of the studies. Four studies
reporting differing definitions of time to next clinical episode of ENL. One study reported
recurrence of new lesions by week 7 in participants who had achieved remission of existing
ENL skin lesions at the end of the first week.17 One study reported relapse of ENL within
52 weeks after treatment.20 Two studies reported recurrence of ENL by the end of the trial
period in participants whose initial reaction was controlled in this same period.21,23
Systemic corticosteroids
Time to next clinical episode of ENL was not reported for any systemic corticosteroid
interventions.
Systemic non-steroidal immunomodulatory therapies
Medium-term: No significant difference in recurrence of new lesions after 7 weeks was
observed between the 100 mg thalidomide regimen and the 300 mg thalidomide regimen (RR
3·75; 95% CI 0·62 to 22·64; n ¼ 13).17 No significant difference in recurrence of ENL was
found between clofazimine and prednisolone at the end of 12 weeks (RR 0·14; 95% CI 0·02 to
1·04; n ¼ 14).21
Long-term: Results showed significantly less participants with relapse of ENL in the
clofazimine group compared to the thalidomide group within 52 weeks after treatment (RR
0·08; 95% CI 0·01 to 0·56; n ¼ 72).20 No significant difference in recurrence of ENL was
observed between indomethacin and chloroquine (RR 1·14; 95% CI 0·44 to 2·94; n ¼ 15),
prednisolone (RR 0·83; 95% CI 0·40 to 1·72; n ¼ 20) or aspirin (RR 0·82; 95% CI 0·38 to
1·74; n ¼ 17) respectively at the end of the trial period (90 days or 12 months).23
(D) CHANGES IN QUALITY OF LIFE
None of the trials reported changes in quality of life.
ADVERSE EVENTS
Three trials did not report on adverse events.19,20,24 The other trials did provide information
about adverse events, but often the number of participants with any adverse events in both
groups was unclear.
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Systemic corticosteroids
Minor adverse events not requiring withdrawal from treatment (swelling of the face, ‘buffalo
hump’, striae distensae and acne) were more often reported in participants who received
intravenous dextrose alone and oral steroids per their need to control ENL (control group)
compared to those who received intravenous betamethosane in 5% dextrose, but the number
of participants with adverse events in each group was not given.12
Systemic non-steroidal immunomodulatory therapies
Withdrawals from thalidomide treatment were caused by intestinal obstruction (1/12
participants),13 and worsening of ENL symptoms (3/22 participants).17 Minor adverse events
not requiring withdrawal from thalidomide treatment (e.g. mild dermatitis, constipation,
nausea, drowsiness, headache, insomnia, dizziness, dryness) were reported, but data for
comparison was unclear or lacking.13 – 16,18 Significantly less participants in the 100 mg
thalidomide regimen group reported any mild to moderate adverse events compared to those
in the 300 mg thalidomide regimen group during the 7-week regimen (RR 0·46; 95% CI 0·23
to 0·93; n ¼ 22).17 Withdrawals from pentoxifylline were due to gastrointestinal intolerance
to the drug (1/24 participants) and fever and continuing lesion inflammation (3/24
participants). Adverse events not requiring withdrawal from pentoxifylline treatment (e.g.
gastrointestinal complaints, nausea) were reported in 2/24 participants.18 Significantly more
participants who received clofazimine had minor adverse events compared to those who
received prednisolone (RR 1·92; 95% CI 1·10 to 3·35; n ¼ 24). In the clofazimine group all
participants had red/black pigmentation. No withdrawals from either clofazimine or
prednisolone treatment were reported.21 Withdrawal from indomethacin treatment was due to
deterioration of ENL (1/16 participants). Minor adverse events (e.g. nausea, dizziness,
insomnia) were more frequently reported in participants who received indomethacin
(9 events) compared to those who received prednisolone (1 event).22 No significant
differences in minor adverse events (e.g. abdominal pain, nausea, headache) were observed
between indomethacin and chloroquine (RR 1·09; 95% CI 0·57 to 2·10; n ¼ 23), prednisolone
(RR 0·92; 95% CI 0·52 to 1·63; n ¼ 24) and aspirin (RR 2·23; 95% CI 0·87 to 5·71; n ¼ 25)
respectively.23
Discussion
SUMMARY OF MAIN RESULTS
There are no good controlled trial data on the optimum treatment for controlling the acute
phase of ENL. Our review included 13 randomised controlled trials involving 445
participants, and assessed the effects of betamethasone, thalidomide, pentoxifylline,
clofazimine, indomethacin and levamisole in the management of ENL. One trial showed
thalidomide treatment to be superior to acetylsalicylic acid treatment (less new reactions
requiring further treatment) in the short-term control of ENL.16 Two trials showed significant
longer-term benefits of clofazimine treatment compared to thalidomide (fewer recurrences)
or prednisolone (more treatment successes) respectively.20,21 Mild to moderate adverse
events were significantly higher in participants taking a 300 mg versus 100 mg dose of
thalidomide17 and in participants taking clofazimine compared with prednisolone.21
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The results should be considered with caution, due to methodological shortcomings. Data
extraction of the study of Iyer et al. was limited to the results of the first randomised treatment
regimen to avoid having more than one outcome per participant in the analysis.16 In another
study participants continued on a maintenance dose of either 100 mg clofazimine or 50 mg
thalidomide daily during the year after therapy. The study found significantly less recurrences
of ENL in the group who received clofazimine therapy and this effect may be due to the
persistance of clofazimine in the body over a longer period of time.20 Karat et al. tapered the
dose of prednisolone (starting at 30 mg daily and tapered off to 5 mg daily), while the dose of
clofazimine (300 mg daily) remained the same during the 12-week treatment.21
QUALITY OF THE EVIDENCE
The quality of trials was generally poor, especially in studies published more than 20 years
ago, due to the lack of clear reporting of methods, data and the allocation process. Most of the
studies were too small (10 to 92 participants) to identify important differences even if they
existed.
Three studies had a cross-over design which is associated with increased risk of bias.13,14,19
We therefore considered only results of the first phase treatment if these data were available.
Two studies used more than one outcome of individual participants in the analysis.15,16 This
may have led to an over-estimate of the effect because the within-patient variance between
outcomes of the same person may be smaller than the between-patient variance of outcomes
between individuals. We used only data of the first randomised treatment to overcome this
concern and these were only available for the trial of Iyer et al.16 Most of the trials reported
co-medication, which may have diluted the effect of the intervention tested in the studies. Most
of the studies were not clear as to how allocation sequences were generated or how allocation
was concealed. Blinding, especially of the outcome assessor, was not described at all or unclear.
Trials assessing clofazimine were unblinded the moment skin discoloration appeared.
This might have biased the outcome assessments. Six studies reported incomplete outcome
data, but only two of those performed an intention to treat analysis. Baseline data were poorly
reported and absent in five studies. Adverse effects were often reported inadequately, limiting
comparisons between experimental and control groups.
Conclusion
IMPLICATIONS FOR PRACTICE
There is some evidence of benefit for thalidomide and clofazimine, but generally we found
insufficient evidence to make any firm recommendations on the use of any of the
interventions tested for management of ENL and included in this review. This does not mean
they do not work, because the studies were generally of poor quality and small-sized.
Treatment with thalidomide showed a significant benefit compared to acetylsalicylic acid
(aspirin). Clofazimine treatment was superior to prednisolone and thalidomide. Current
guidelines for the management of ENL are given by bodies such as the World Health
Organization (WHO) and the International Federation of Anti-Leprosy Associations (ILEP),
but these guidelines are not supported by evidence from randomised controlled trials and are
developed from practice.
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Most of the studies reported adverse effects of treatment. Mild to moderate adverse events
were significantly higher in participants taking a 300 mg versus 100 mg dose of thalidomide
and in participants taking clofazimine compared with prednisolone. Only in a few instances
withdrawal from treatment was required, but it was not always clear whether this was due to
treatment or for another reason. Adverse effects of commonly used drugs, such as
prednisolone, clofazimine and thalidomide are well-documented and should be kept in mind
when prescribing drugs for ENL.
IMPLICATIONS FOR RESEARCH
The 13 trials included in this review were generally of poor methodological quality and have
mostly been of short duration. A wide range of interventions were assessed, one trial
evaluated betamethasone, five trials thalidomide, one trial pentoxifylline, three trials
clofazimine, two trials indomethacin and one trial levamisole.
It was often unclear what the duration and severity of ENL was before the starting of
treatment. Future studies should have clearer case definitions for ENL and we recommend
that different durations of ENL (single acute episode, multiple acute episode or chronic) and
different severity of ENL (mild or severe) be distinguished, as such subgroups may need
different management of ENL.
Erythema nodosum leprosum is a complicated disease known for its unpredictability, its
variable severity and duration, and its often chronic and recurrent nature. Although most
agents may work similarly for controlling the acute symptoms of ENL, prevention of
recurrences is far more difficult.
There is a need for good quality studies which follow the current standards for design and
reporting of randomised controlled trials, and for large multi-centre studies to ensure that
enough participants are enrolled.
None of the studies investigated whether the interventions improved quality of life of
participants and only a few examined the long-term effects of interventions. There is a need
for clearly defined outcome measures, both at short-term and longer-term. We would
recommend that future studies include outcomes, such as absence of new tender
erythematous subcutaneous skin lesions at completion of the ENL therapy, disappearance
of ENL associated inflammation at other sites than the skin (such as iritis and arthritis) at
completion of the ENL therapy, time to next clinical episode of ENL after completion of
treatment, and quality of life measures.
It is recommended that internationally recognised and validated severity scales be
developed so that results from different countries can be compared.
A trial comparing directly prednisolone and thalidomide has never been done, and is
urgently needed.
Future studies should aim to assess the efficacy, safety and optimal regimens of
prednisolone and thalidomide for severe ENL and clofazimine for mild ENL as well as other
potentially beneficial therapies.
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